Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CVM | Options | Award | $500 | +50K | +6.77% | $0.01* | 789K | Nov 19, 2021 | Common Stock | 50K | $10.48 | Direct | F1 |
Id | Content |
---|---|
F1 | Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.48 per share. The stock options vest 100% upon the approval of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia. None of the options will be exercisable before November 19, 2022. |